Filtered By:
Infectious Disease: Tuberculosis
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 482 results found since Jan 2013.
Blood test can predict risk of developing tuberculosis
(NIH/National Institute of Allergy and Infectious Diseases) Only a fraction of those infected with the bacterium that causes TB ever develops symptomatic illness. Now, an international team of researchers has identified biological markers in the blood of latently infected people that may lead doctors to a way to predict who is at high risk of developing active TB. If validated, a test based on these blood biomarkers would allow doctors to target therapies to at-risk people, thus preventing them from getting sick.
Source: EurekAlert! - Infectious and Emerging Diseases - March 23, 2016 Category: Infectious Diseases Source Type: news
U.S. Officials Warn Zika 'Scarier' Than Initially Thought
By Timothy Gardner and Jeff Mason WASHINGTON (Reuters) - Top health officials expressed heightened concern on Monday about the threat posed to the United States by the Zika virus, saying the mosquito that spreads it is now present in about 30 states and hundreds of thousands of infections could appear in Puerto Rico. At a White House briefing, they stepped up pressure on the Republican-led Congress to pass approximately $1.9 billion in emergency funding for Zika preparedness that the Obama administration requested in February. "Everything we look at with this virus seems to be a bit scarier than we initially thought," said...
Source: Healthy Living - The Huffington Post - April 12, 2016 Category: Consumer Health News Source Type: news
Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
Authors: Singh S, Sharma D, Suri D, Gupta A, Rawat A, Rohit MK
Abstract
This was a single-centre study to evaluate the usefulness of tumour necrosis factor-α (TNF-α) blocker, infliximab (IFX), for treatment of Kawasaki disease (KD) in children in Northern Indian. The study was carried out in the Paediatric Allergy-Immunology Unit, Advanced Paediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh. The study period was January 2007 to March 2015. Review of records of 23 children with KD who had received IFX was carried out. Median age at presentation was 2 years (range 2 months to 1...
Source: Clinical and Experimental Rheumatology - April 19, 2016 Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
Conclusions
Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
Source: Annals of the Rheumatic Diseases - May 9, 2016 Category: Rheumatology Authors: Winthrop, K. L., Park, S.-H., Gul, A., Cardiel, M. H., Gomez-Reino, J. J., Tanaka, Y., Kwok, K., Lukic, T., Mortensen, E., Ponce de Leon, D., Riese, R., Valdez, H. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research
Treatment of Tuberculosis — Adjuvant Therapies to Increase the Efficiency of Antibiotics
There is growing evidence that resistance to Mycobacterium tuberculosis infection is governed in large part by the regulation of host cell death. Lipid mediators called eicosanoids are thought to play a central role in this process. The subject invention is a novel method of enhancing the efficacy of antibiotic treatments for Mycobacterium tuberculosis infection by co-administering an inhibitor of 5-lipoxygenase and a COX-2 dependent prostaglandin. Inhibition of 5-lipoxygenase and treatment with prostaglandin E2 results in alteration of the eicosanoid balance. The synergistic effects of altering the eicosanoid balance and...
Source: NIH OTT Licensing Opportunities - November 18, 2011 Category: Research Authors: admin Source Type: research
Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models
Abstract
Abnormal toll-like receptor (TLR) activation and uncontrolled resolution of inflammation are suspected to play a key role in the development of autoimmune diseases. Acquired myasthenia gravis (MG) is an invalidating neuromuscular disease leading to muscle weaknesses. MG is mainly mediated by anti-acetylcholine receptor (AChR) autoantibodies, and thymic hyperplasia characterized by ectopic germinal centers is a common feature in MG. An abnormal expression of certain TLRs is observed in the thymus of MG patients associated with the overexpression of interferon (IFN)-β, the orchestrator of thymic changes in...
Source: Clinical Reviews in Allergy and Immunology - May 19, 2016 Category: Allergy & Immunology Source Type: research
TB still a risk in psoriasis patients taking TNF blockers
Despite following guidelines aimed at reducing the likelihood of tuberculosis infection in patients with psoriasis treated with tumor necrosis factor antagonists, a French study has identified a number of active TB cases in this patient group.
The nationwide retrospective study identified 12 cases...
Source: Skin and Allergy News - June 15, 2016 Category: Dermatology Source Type: news
Dilemma of managing asymptomatic children referred with 'culture-confirmed drug-resistant tuberculosis
Conclusions
Bacteriological evaluation should not be performed in the absence of any clinical indication. If drug-resistant Mycobacterium tuberculosis is detected in an asymptomatic child with a normal chest radiograph, close observation may be an appropriate strategy, especially in settings where potential laboratory error and poor record keeping are constant challenges.
Source: Archives of Disease in Childhood - June 16, 2016 Category: Pediatrics Authors: Loveday, M., Sunkari, B., Marais, B. J., Master, I., Brust, J. C. M. Tags: Immunology (including allergy), Drugs: infectious diseases, HIV/AIDS, Child health, Radiology, Sexual health, Clinical diagnostic tests, Radiology (diagnostics) Original article Source Type: research
Zika and the race to quell outbreaks: My talk with Anthony Fauci, NIH ’ s top vaccine expert
Anthony Fauci has spent his career hunting ways to treat and prevent infectious diseases, from tuberculosis to severe acute respiratory syndrome, or SARS. He did pioneering work on deciphering how HIV/AIDS attacks the human immune system, and during more than three decades as director of the National Institute of Allergy and Infectious Diseases has continued […]See the rest of the story at mysite.comRelated:WHO will vaccinate in five African nations after polio outbreakFederal emergency aid is ending in Flint. State officials vow to pay for water.Baltimore police cuffed, stunned and shot people in mental health crisi...
Source: Washington Post: To Your Health - August 15, 2016 Category: Consumer Health News Source Type: news
Microwave-assisted Synthesis of 2-Styrylquinoline-4-carboxylic Acids as Antitubercular Agents.
Conclusion: Three compounds had activity under aerobic conditions.
PMID: 27585570 [PubMed - as supplied by publisher]
Source: Medicinal Chemistry - August 31, 2016 Category: Chemistry Authors: Muscia GC, Asis SE, Buldain GY Tags: Med Chem Source Type: research
NIH-funded researchers find signs TB can persist in lungs despite treatment
(NIH/National Institute of Allergy and Infectious Diseases) It has been known that the microbe that causes TB, Mycobacterium tuberculosis, can persist in the lungs even after patient tissue samples test negative for the bacteria. In new research appearing in Nature Medicine, intramural researchers at the NIAID its grantees found through the use of positron emission tomography/computerized tomography scanning that TB lesions can remain in the lungs long after treatment with antibiotics has been completed.
Source: EurekAlert! - Infectious and Emerging Diseases - September 6, 2016 Category: Infectious Diseases Source Type: news
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions?
CONCLUSION: Adverse drug reaction anti-TB drugs whatever form is not an uncommon. Hematologic effects significantly higher in patients treated with FDCs and Significant difference in doses of Isoniazid and Rifampicin can be the reason of these.
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Majdoub, S., Daghfouss, H., Ben Saad, S., Ben Tkhayat, A., Tritar, F. Tags: 5.3 Allergy and Immunology Source Type: research
Rifamycin induced leukocytoclastic vasculitis. A rare side-effect of anti-tuberculous chemotherapy
We describe a case of leucocytoclastic vasculitis (LCV) caused by rifamycins.A 53 year old female presented with cough, night sweats and upper lobe nodules. Bronchial-alveolar lavage confirmed fully sensitive mycobacterium tuberculosis (TB).She commenced treatment with rifampicin, isoniazid, ethambutol and pyrizinazmide. At 4 weeks she developed an extensive purpuric rash, malaise and joint aches. There was no evidence of other infections or connective tissue disorders on extensive screening. Her inflammatory markers were elevated. A punch biopsy of her shin demonstrated leukocytoclastic vasculitis of the superficial dermi...
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Ewence, A., Dodd, J., Tewari, A., Akhras, V., Aul, R. Tags: 10.2 Tuberculosis Source Type: research
